A phase III study to evaluate 24- and 48-week response-guided treatment with telaprevir in combination with VX 222, pegylated interferon alpha 2a, and ribavirin in patients with genotype 1 chronic hepatitis C and who have not responded (partial and null responders) to at least one prior course of treatment with pegylated interferon alpha 2a and ribavirin alone.
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2011
At a glance
- Drugs Interferon alpha-2a; Lomibuvir; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- 09 Nov 2011 New trial record